As medical cannabis gains recognition for its therapeutic benefits, academic research is crucial to unlocking its potential. The University of Oxford is at the forefront of this effort, conducting pioneering studies and forging collaborations to explore cannabis-based treatments for a range of health conditions. Their ground-breaking work is advancing knowledge and shaping the future of cannabis as a medical tool.
Understanding Medical Cannabis
Medical cannabis refers to the use of cannabis-derived compounds, particularly THC (tetrahydrocannabinol) and CBD (cannabidiol), to alleviate symptoms of various medical conditions.
- THC: Known for its psychoactive effects.
- CBD: Valued for anti-inflammatory, anxiolytic, and pain-relieving properties without causing intoxication.
Legalisation of Medical Cannabis
Medical cannabis was legalised in the UK in November 2018, following the high-profile case involving Alfie Dingley with severe epilepsy. The new law allowed registered specialist doctors to prescribe cannabis-based medicinal products (CBMPs) under strict regulations. Despite this significant milestone, access to medical cannabis remains heavily restricted.
Conditions Eligible for Prescription
Under NHS guidelines, medical cannabis prescriptions are available for a limited number of conditions:
- Severe epilepsy (e.g., Lennox-Gastaut syndrome and Dravet syndrome).
- Chemotherapy-induced nausea and vomiting.
- Muscle spasticity in multiple sclerosis (MS).
Medications like Epidyolex (a CBD-based treatment for epilepsy) and Sativex (used for MS spasticity) are among the few licensed options. However, obtaining an NHS prescription requires patients to exhaust other treatment options first, and the process is highly regulated. In fact, in 2021, only 977 NHS prescriptions for CBMPs were issued, highlighting the challenges of accessing through public healthcare and the reliance on registered medical cannabis clinics.
Private Clinics and Broader Access
Private clinics provide greater flexibility, prescribing cannabis-based medicines for conditions beyond those recognised by the NHS, such as chronic pain and anxiety. With this service only being allowed by following consultation and a prescription from a GMC registered specialist doctor, which all the best cannabis clinic‘s should have.
The University of Oxford’s Role in Cannabis Research
In 2017, Oxford launched a £10 million research programme to study cannabinoid biomedicine, with a focus on developing therapies for conditions such as pain, cancer, and inflammatory diseases.
The University of Oxford leads global efforts to expand the therapeutic applications of cannabis. Key initiatives include:
STEP Programme:
- Funded by a £16.5 million grant from the Wellcome Trust, the Stratification and Treatment in Early Psychosis (STEP) programme is a ground-breaking international trial.
- It investigates CBD’s efficacy in treating psychosis and preventing its onset in high-risk individuals, involving over 1,000 participants across Europe and North America.
- The trial uses Epidyolex, a pharmaceutical-grade CBD supplied by Jazz Pharmaceuticals, to explore new avenues for psychosis treatment.
Partnership with Oxford Cannabinoid Technologies (OCT):
- A collaboration to develop cannabis-based therapies for pain management, cancer, and inflammation.
- Combines Oxford’s scientific expertise with OCT’s biopharmaceutical innovation to push the boundaries of cannabinoid medicine.
Biomarkers for Personalised Medicine:
Research within the STEP programme focuses on identifying biomarkers—biological indicators predicting patient responses to treatments.
This work could revolutionise personalised medicine, tailoring therapies to individual needs.
Oxford’s cutting-edge research and collaborations place it at the forefront of evidence-based cannabis medicine, offering hope for patients with chronic and complex conditions.
Addressing Barriers to Access
Despite the legalisation of medical cannabis in the UK in 2018, access remains restrictive. NHS prescriptions are limited to specific conditions, often requiring patients to exhaust other treatment options first. Private clinics provide more flexibility but are cost-prohibitive for many.
Oxford is working to address these barriers through:
- Collaboration with regulatory bodies to ensure safe and ethical cannabis research.
- Partnerships with industry leaders like Jazz Pharmaceuticals and OCT to accelerate the development and accessibility of treatments.
The Future of Cannabis Research at Oxford
Oxford is leading the evolution of medical cannabis research, with a focus on:
- Neurodegenerative Diseases: Exploring cannabinoids’ potential in treating Alzheimer’s and Parkinson’s diseases.
- Personalised Medicine: Customising treatments based on biomarkers to enhance efficacy and minimise side effects.
- Global Leadership: Strengthening its role as a hub for cannabis research, supported by world-class facilities and international partnerships.
Ethical and Legal Considerations
Cannabis research must navigate a complex regulatory environment. Oxford prioritises:
- Adherence to stringent ethical standards.
- Ensuring patient safety through rigorous clinical trials.
- Transparent collaborations with industry and government bodies.
These efforts are critical for advancing cannabis-based medicine responsibly while maintaining public trust.
Conclusion
The University of Oxford is leading medical cannabis research with innovative studies, global collaborations, and a commitment to advancing patient care. From psychosis treatments to personalised medicine, its work is transforming the field and offering new hope for patients worldwide.
As research progresses, the insights and breakthroughs from Oxford will shape the future of healthcare, making cannabis-based therapies more accessible and effective. Continued investment and collaboration between public and private sectors are essential to unlocking the full potential of medical cannabis.
